Abstract
Objective: Colchicine therapy is complicated by frequent gastrointestinal adverse effects. Methods: We compared intestinal permeability in 21 patients with familial Mediterranean fever on long-standing colchine therapy (mean 5.8 years) and significant gastrointestinal complaints and 12 untreated patients and 14 healthy volunteers. The double probe (lactulose/mannitol) permeability test was performed using a hyperosmolar test solution (1580 mosmol) and the differential urinary recovery ratios were calculated.
Results: Familial Mediterranean fever patients on colchicine therapy had significantly higher lactulose/mannitol urinary excretion ratios (0.073) compared to untreated patients (0.035) and to healthy controls (0.021). Untreated familial Mediterranean fever patients had significantly greater urinary lactulose/mannitol recovery ratios than controls (P < 0.02). No correlation was found between the degree of enhanced permeability and the length of exposure to the drug or the severity of clinical symptoms.
Conclusion: Intestinal permeability was significantly enhanced in patients with familial Mediterranean fever treated with colchicine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 19 February 1996/Accepted in revised form: 9 July 1996
Rights and permissions
About this article
Cite this article
Fradkin, A., Yahav, J., Diver-Haber, A. et al. Colchicine enhances intestinal permeability in patients with familial Mediterranean fever. E J Clin Pharmacol 51, 241–245 (1996). https://doi.org/10.1007/s002280050191
Issue Date:
DOI: https://doi.org/10.1007/s002280050191